- Dianthus Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Magenta Therapeutics Inc Definitive Merger Agreement with Dianthus Therapeutics Inc - M&A Call TranscriptMay 03, 2023
- Magenta Therapeutics Inc Update on MGTA-117 - Corporate Call TranscriptDec 13, 2022
- Magenta Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 13, 2022
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Magenta Therapeutics Inc MGTA-145 MM Phase 2 Clinical Trial Results Call TranscriptMay 12, 2021
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 11, 2020
- Magenta Therapeutics, Inc. - Special Call TranscriptMay 07, 2020
- Magenta Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Magenta Therapeutics Inc ASH 2019 TranscriptDec 08, 2019
- Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 11, 2019
Magenta Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
© -
Hi, everyone, and welcome to this session at the 31st Annual Credit Suisse Healthcare Conference. I'm Judah Frommer, one of the senior biotech analysts here at CS. We're very excited to have Magenta Therapeutics presenting. And we have Jason Gardner, the CEO, President and Co-Founder. Jason, I'll pass it over to you now.
Thank you, Judah. Good morning, everybody. And thank you also to the Credit Suisse team for the opportunity to present today about -- on Magenta Therapeutics. I will share my screen and a slide deck that I will use today, and that should be visible full size. So we're going to talk today about where we are at Magenta Therapeutics with our progress in transforming the field of stem cell transplant. Big area, big opportunity, ripe for innovation. We're going to talk about our antibody drug conjugate programs, and in particular, focus on our clinical progress and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)